About 65% of women diagnosed with breast cancer don't meet national exercise recommendations after they've been diagnosed, and Black women are much less likely to meet exercise recommendations than white women.
Electroacupuncture ‚Äì a type of acupuncture where a small electric current passes between pairs of acupuncture needles ‚Äì has been found to ease fatigue, anxiety, and depression in women diagnosed with early-stage breast cancer who are taking an aromatase inhibitor.
Early results suggest that treating just the area around where a cancer used to be with radiation may be as good as treating the whole breast with radiation.
Hypofractionated radiation after lumpectomy offers better quality of life than conventional schedule.
A study suggests that women 67 and older diagnosed with early-stage breast cancer are more satisfied cosmetically with lumpectomy and brachytherapy compared to other treatment options.
A study has found that women older than 80 diagnosed with early-stage, hormone-receptor-negative breast cancer don't get survival benefits from chemotherapy.
Non-white women have more severe pain with advanced breast cancer than white women.
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.
A new study shows that women who smoked and got radiation therapy to treat breast cancer had a much higher risk of lung cancer later on compared to women who got radiation and didn't smoke.
While most women having breast cancer surgery won't develop an infection, research shows that infections after breast surgery happen more often than expected.
Measuring the Ki-67 protein in breast cancers doesn't help decide who would benefit from chemotherapy in women diagnosed with hormone-receptor-positive, node-negative disease.
A new study shows that breast cancers that are hormone-receptor-positive and later-stage are more likely to come back later than 5 years after diagnosis and treatment compared to cancers that are hormone-receptor-negative and early-stage.
A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.
Women who had lumpectomy to treat an initial breast cancer and then had lumpectomy again to treat breast cancer that came back in the same breast had lower survival rates in the 10 years after the second surgery compared to women who had lumpectomy as the first surgery and then mastectomy as the second surgery.
In a small study, internal radiation after lumpectomy didn't cause the capsules of existing breast implants to contract, leading to good cosmetic results.
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
During the past 60 years, the average number of women who survived for 10 years after being diagnosed with breast cancer and treated at the University of Texas MD Anderson Cancer Center tripled.
New research suggests that lymphedema may be more common and last longer than generally thought.
Research suggests that a careful weight lifting program that starts with light weights and gradually increases after breast cancer surgery doesn't increase lymphedema risk and could possibly lower the risk of developing lymphedema.
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
A large study found that women treated with hormonal therapy for breast cancer were 87% less likely to die from lung cancer compared to the average person's risk of dying from lung cancer.
A small, early study suggests that some advanced-stage cancers may respond to an experimental combination of iniparib and Camptosar.
A large study found that iniparib didn't improve survival in women diagnosed with metastatic triple-negative breast cancer, which contradicts results from earlier studies.